GCG and Coma: Given that saxagliptin was the top prediction for both acute and prolonged DOC, we conducted a retrospective cohort analysis to evaluate whether saxagliptin and other incretin-based therapies were associated with improved outcomes following acute coma relative to other diabetes medications.